230 related articles for article (PubMed ID: 31841221)
1. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma.
Siddiqui SA; Frigola X; Bonne-Annee S; Mercader M; Kuntz SM; Krambeck AE; Sengupta S; Dong H; Cheville JC; Lohse CM; Krco CJ; Webster WS; Leibovich BC; Blute ML; Knutson KL; Kwon ED
Clin Cancer Res; 2007 Apr; 13(7):2075-81. PubMed ID: 17404089
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
Chang K; Qu Y; Dai B; Zhao JY; Gan H; Shi G; Zhu Y; Shen Y; Zhu Y; Zhang H; Ye D
Sci Rep; 2017 May; 7(1):2074. PubMed ID: 28522811
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in nonclear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gray KP; Callea M; Ho TH; Albiges L; Bellmunt J; Song J; Carvo I; Lampron M; Stanton ML; Hodi FS; McDermott DF; Atkins MB; Freeman GJ; Hirsch MS; Signoretti S
Ann Oncol; 2014 Nov; 25(11):2178-2184. PubMed ID: 25193987
[TBL] [Abstract][Full Text] [Related]
6. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
9. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
[TBL] [Abstract][Full Text] [Related]
10. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.
Baine MK; Turcu G; Zito CR; Adeniran AJ; Camp RL; Chen L; Kluger HM; Jilaveanu LB
Oncotarget; 2015 Sep; 6(28):24990-5002. PubMed ID: 26317902
[TBL] [Abstract][Full Text] [Related]
11. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
[TBL] [Abstract][Full Text] [Related]
12. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
Bonanno L; Pavan A; Dieci MV; Di Liso E; Schiavon M; Comacchio G; Attili I; Pasello G; Calabrese F; Rea F; Favaretto A; Rugge M; Guarneri V; Fassan M; Conte PF
Eur J Cancer; 2018 Sep; 101():191-200. PubMed ID: 30077124
[TBL] [Abstract][Full Text] [Related]
13. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of the tumor immune microenvironment in synovial sarcoma.
Oike N; Kawashima H; Ogose A; Hotta T; Hatano H; Ariizumi T; Sasaki T; Yamagishi T; Umezu H; Endo N
Cancer Sci; 2018 Oct; 109(10):3043-3054. PubMed ID: 30133055
[TBL] [Abstract][Full Text] [Related]
16. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Analysis of Foxp3
Stasikowska-Kanicka O; Wągrowska-Danilewicz M; Danilewicz M
Pathol Oncol Res; 2018 Jul; 24(3):497-505. PubMed ID: 28669079
[TBL] [Abstract][Full Text] [Related]
18. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
[TBL] [Abstract][Full Text] [Related]
19. Role of immune microenvironment in gastrointestinal stromal tumours.
Blakely AM; Matoso A; Patil PA; Taliano R; Machan JT; Miner TJ; Lombardo KA; Resnick MB; Wang LJ
Histopathology; 2018 Feb; 72(3):405-413. PubMed ID: 28871595
[TBL] [Abstract][Full Text] [Related]
20. Comparative analyses of tumour immune microenvironment between collecting duct carcinoma and fumarate hydratase-deficient renal cell carcinoma.
Kiyozawa D; Kohashi K; Takamatsu D; Umekita S; Eto M; Kinjo M; Nishiyama K; Taguchi K; Oshiro Y; Kuboyama Y; Oda Y
J Clin Pathol; 2024 Jan; 77(2):105-110. PubMed ID: 36347592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
